Wednesday, October 21, 2026
Saga
Novo Nordisk obesity pipeline and investor reset
Overview
Description Novo Nordisk is trying to reset investor confidence in its obesity and metabolic-drug franchise through pipeline targets, licensing deals and rival data. Overview Novo outlined plans for new blockbuster drugs, obesity and diabetes candidates, and more than 150 billion Danish kroner in pipeline-drug sales by 2035…
Keeping an eye on this saga?
Tilt can alert you when its scenarios shift, or send you a recommendation when one crosses a threshold.
Stories in this saga
4 stories, 5 sources
Sep 21, 2026
Sep 25, 2026
